Drugs / TRASTUZUMAB MAFODOTIN
TRASTUZUMAB MAFODOTIN
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05872295 | Sep 2023 → Dec 2026 expected | breast cancer, gastric cancer, gastroesophageal cancer | Iksuda Therapeutics Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT03944499 | Oct 2019 → May 2024 | breast cancer | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05755048 | Mar 2023 → Jul 2025 | breast cancer | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRASTUZUMAB MAFODOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068604 ↗ |
| Known as | FS-1502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755048 ↗ |
| Known as | IKS014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05872295 ↗ |
| Known as | Lcb-14 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068604 ↗ |
| Known as | Lcb14-0110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068604 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-HER2 Humanized Monoclonal Antibody” NCT05755048 ↗ |
| Route | Intravenous | “0.1 mg/kg, IV” NCT03944499 ↗ |